I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen. Yeah. Well, first, companies in our space are ...

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

Lisa Shafer, a vice president at biotech firm Biogen, will keynote the conference ... Also at the event, former Axonics CEO ...

Technology company Cisco is among the groups involved in six virtual power purchase agreements (VPPAs) to secure energy from ...

Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping ... That, along with a $165 million payment from Biogen (BIIB) it received this ...